Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 4/20 | 0.55 |
| ▸ | CES1 | P23141 | 4/20 | 0.55 |
| ▸ | BCHE | P06276 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | ALB | P02768 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.39 |
| ▸ | FEN1 | P39748 | 1/20 | 0.39 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL138307 | 0.85 | PTPN1 (0.53) | CES2CES1HPGDMAPTMEN1 | |
| SCHEMBL16253911 | 0.83 | MAPT (0.48) | CES2CES1MAPTMEN1KMT2A | |
| SCHEMBL30440405 | 0.83 | MAPT (0.48) | CES2CES1MAPTMEN1KMT2A | |
| SCHEMBL12694512 | 0.83 | MAPT (0.46) | CES2CES1BCHEHPGDMAPT | |
| SCHEMBL7001279 | 0.79 | CES2 (0.50) | CES2CES1HPGDMAPTMEN1 | |
| SCHEMBL7015329 | 0.79 | ALDH1A1 (0.54) | MAPTMEN1KMT2AALDH1A1CYP1A2 | |
| SCHEMBL395494 | 0.78 | MAPT (0.56) | HPGDMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL3761126 | 0.78 | HPGD (0.59) | CES2CES1BCHEHPGDMAPT | |
| SCHEMBL15990788 | 0.77 | CES2 (0.63) | CES2CES1BCHEHPGDMEN1 | |
| SCHEMBL14396511 | 0.77 | CES2 (0.63) | CES2CES1BCHEHPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2488519-B1 | PYRAZOLOPYRIDINE DERIVATIVES AS ANTICANCER AGENT | PF MEDICAMENT (FR) | 2015-06-10 | — | — | EP | disclosed |
| US-8889711-B2 | Pyrazolopyridine derivatives as anticancer agent | PIERRE FABRE MEDICAMENT (FR) | 2014-11-18 | — | — | US | disclosed |
| US-20120245170-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS ANTICANCER AGENT | PIERRE FABRE MEDICAMENT (FR) | 2012-09-27 | — | — | US | disclosed |
| US-7705029-B2 | Acrylonitrile derivatives for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2010-04-27 | — | — | US | disclosed |
| US-7705029-B2 | Acrylonitrile derivatives for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2010-04-27 | — | — | US | disclosed |
| US-7705029-B2 | Acrylonitrile derivatives for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2010-04-27 | — | — | US | disclosed |
| EP-1732900-A4 | ACRYLONITRILE DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2007-12-12 | — | — | EP | disclosed |
| US-20070270478-A1 | ACRYLONITRILE DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2007-11-22 | — | — | US | disclosed |
| US-20070270478-A1 | ACRYLONITRILE DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2007-11-22 | — | — | US | disclosed |
| US-20070270478-A1 | ACRYLONITRILE DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2007-11-22 | — | — | US | disclosed |
| US-7202232-B2 | Acrylonitrile derivatives for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202232-B2 | Acrylonitrile derivatives for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202232-B2 | Acrylonitrile derivatives for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-04-10 | — | — | US | disclosed |
| EP-1732900-A2 | ACRYLONITRILE DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2006-12-20 | — | — | EP | disclosed |
| US-20060046999-A1 | Monocyclic aroylpyridinones as antiinflammatory agents | BAYER HEALTHCARE AG (DE) | 2006-03-02 | — | — | US | disclosed |
| US-20050272699-A1 | Acrylonitrile derivatives for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. | 2005-12-08 | — | — | US | disclosed |
| WO-2005091752-A2 | ACRYLONITRILE DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060046999-A1 | Monocyclic aroylpyridinones as antiinflammatory agents | PTGIS, PTGES, PTGES2 | CES2 2982/4885CES1 1526/4885BCHE 1156/4885 |
| US-20120245170-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS ANTICANCER AGENT | DPYD, TYMP, ABCB1 | CES2 4189/4885CES1 3253/4885BCHE 4515/4885 |
| US-20050272699-A1 | Acrylonitrile derivatives for inflammation and immune-related uses | IL1B, IL6, TLR4 | CES2 431/4885CES1 751/4885BCHE 3823/4885 |
| US-20070270478-A1 | ACRYLONITRILE DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | IL1B, IL6, TLR4 | CES2 431/4885CES1 751/4885BCHE 3823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.